Can China bring its own pipeline to the market?

被引：7

作者：

Louët, S

机构：

来源：

NATURE BIOTECHNOLOGY | 2004年 / 22卷 / 12期

关键词：

D O I：

10.1038/nbt1204-1497

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

China is a growing biotech player whose main competitive edge lies in low development costs. But will inexperienced money men and a disinterested pharmaceutical industry hold it back? Sabine Louët investigates.

引用

页码：1497 / 1499

页数：3

共 8 条

[1]

ANSCOMB A, 2004, KALORAMA INFORMATION

[2] Trading on traditional medicines [J].

Basu, P .

NATURE BIOTECHNOLOGY, 2004, 22 (03) :263-265

[3]

*GEN BIOL, 2004, CHIN PIP 2004

[4] IP litigation in China could drive innovation [J].

Jia, HP .

NATURE BIOTECHNOLOGY, 2004, 22 (04) :368-368

[5]

LIU JL, 2003, BIOENTREPRENEUR 1106

[6]

LIU JL, 2003, BIOENTREPRENEUR 1023

[7]

MCNEIL DG, 2004, NY TIMES 0514

[8] China approves first gene therapy [J].

Pearson, S ;

Jia, HP ;

Kandachi, K .

NATURE BIOTECHNOLOGY, 2004, 22 (01) :3-4

← 1 →